Who are Gamunex Intravenous Immunoglobulin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PRIVIGEN (CSL Behring), IGIV GAMMAGARD LIQUID/KIOVIG, Ig NextGen 10%, IgNextGen 16%, IGIV3I Grifols, LIV-GAMMA SN Inj.10%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gamunex-intravenous-immunoglobulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Gamunex Intravenous Immunoglobulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gamunex Intravenous Immunoglobulin (Gamunex Intravenous Immunoglobulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous Immunoglobulin (IVIG). Area: Immunology.

phase 3 Intravenous Immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Gamunex Intravenous Immunoglobulin (Gamunex Intravenous Immunoglobulin) — National Institute of Mental Health (NIMH). Gamunex is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to enhance immune function and modulate inflammatory responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gamunex Intravenous Immunoglobulin TARGET	Gamunex Intravenous Immunoglobulin	National Institute of Mental Health (NIMH)	phase 3	Intravenous Immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
PRIVIGEN (CSL Behring)	PRIVIGEN (CSL Behring)	Hospices Civils de Lyon	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies
IGIV GAMMAGARD LIQUID/KIOVIG	IGIV GAMMAGARD LIQUID/KIOVIG	Baxalta now part of Shire	phase 3	Intravenous immunoglobulin (IGIV)	Fc receptors, complement system, pathogenic antigens
Ig NextGen 10%	Ig NextGen 10%	CSL Limited	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
IgNextGen 16%	IgNextGen 16%	CSL Limited	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
IGIV3I Grifols	IGIV3I Grifols	Instituto Grifols, S.A.	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
LIV-GAMMA SN Inj.10%	LIV-GAMMA SN Inj.10%	SK Plasma Co., Ltd.	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous Immunoglobulin (IVIG) class)

National Institute of Mental Health (NIMH) · 1 drug in this class
Octapharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gamunex Intravenous Immunoglobulin — Competitive Intelligence Brief. https://druglandscape.com/ci/gamunex-intravenous-immunoglobulin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab